Strategy to provide a useful solution to effective delivery of dihydroartemisinin: Development, characterization and in vitro studies of liposomal formulations

Colloids and Surfaces B: Biointerfaces

Volumn 116, Issue , 2014, Pages 121-127

  Righeschi, Chiara ^a   Coronnello, Marcella ^a   Mastrantoni, Azzurra ^a   Isacchi, Benedetta ^a   Bergonzi, Maria Camilla ^a   Mini, Enrico ^a   Bilia, Anna Rita ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Albumin; Cellular uptake; Cytotoxicity against MCF 7 cell line; Dihydroartemisinin liposomes; Flow cytometry

Indexed keywords

ALBUMIN; CELLULAR UPTAKE; CELLULAR UPTAKE EFFICIENCY; DIHYDROARTEMISININ; ENCAPSULATION EFFICIENCY; MCF-7 CELLS; PHYSICAL CHARACTERISTICS; POORLY WATER-SOLUBLE DRUGS;

BIOCHEMISTRY; CELL CULTURE; CELL DEATH; CHOLESTEROL; CYTOTOXICITY; ENCAPSULATION; FLOW CYTOMETRY;

LIPOSOMES;

ALBUMIN; CHOLESTEROL; DIHYDROARTEMISININ; DRUG CARRIER; LIPOSOME; MACROGOL 2000; ALBUMINOID; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; LISSAMINE RHODAMINE B; RHODAMINE; SOLUTION AND SOLUBILITY;

ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CELL TRANSPORT; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; DRUG STABILITY; DRUG UPTAKE; ENCAPSULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; INTERNALIZATION; LIPOSOMAL DELIVERY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ZETA POTENTIAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MCF 7 CELL LINE; SOLUTION AND SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ALBUMINS; ANTINEOPLASTIC AGENTS; ARTEMISININS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIPOSOMES; MCF-7 CELLS; RHODAMINES; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84892881127     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.12.019     Document Type: Article

References (28)

1. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
2. Fahr A., Liu X. Delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 2007, 4:403-416.
3. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
4. Efferth T., Rücker G., Falkenberg M., Manns D., Olbrich A., Fabry U., Osieka R. Detection of apoptosis in KG-1a leukemic cells treated with investigational drugs. Arzneimittelforschung. 1996, 46:196-200.
5. Lai H., Sing N.P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 1995, 91:41-46.
6. Efferth T., Dunstan H., Sauerbrey A., Miyachi H., Chitambar C.R. The anti-malarial artesunate is also active against cancer. Int. J. Oncol. 2001, 18:767-773.
7. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., Hengstler J.G., Halatsch M.E., Volm M., Tew K.D., Ross D.D., Funk J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64:382-394.
8. Lu Y., Chen T.S., Qu J.L., Pan W.L., Sun L., Wei X.B. Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC a-1 cells. J. Biomed. Sci. 2009, 16:1-15.
9. Kim S.J., Kim M.S., Lee J.W., Yoo H. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. Cancer Res. Clin. Oncol. 2006, 132:129-135.
10. Gabriëls M., Plaizier-Vercammen J. Design of a dissolution system for the evaluation of the release rate characteristics of artemether and dihydroartemisinin from tablets. Int. J. Pharm. 2004, 274:245-260.
11. Batty K.T., Davis T.M.E., Thu L.T.A., Binh T.Q., Anh T.K. Selective high performance liquid chromatographic determination of artesunate and α- and β dihydroartemisinin in patients with falciparum malaria. J. Chromatogr. 1996, 677:345-350.
12. Panagi Z., Avgoustakis K., Evangelatos G., Ithakissios D.S. In vitro binding of HSA, IgG, and HDL on liposomes of different composition and its correlation with the BLOOD/RES ratio of liposomes. Int. J. Pharm. 1999, 176:203-207.
13. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo: relation to circulation lifetimes. J. Biol. Chem. 1992, 267:18759-18765.
14. Owens D., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
15. Jeon S.I., Lee J.H., Andrade J.D., De Gennes P.G. Protein surface interactions in the presence of polyethylene oxide. 1. Simplified theory. J. Colloid Interface Sci. 1991, 142:49-158.
16. Woodle M.C., Newman M.S., Choen J.A. Sterically stabilized liposomes: physical and biological properties. J. Drug Target. 1994, 2:397-403.
17. Oku N., Namba Y. Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11:231-270.
18. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61:428-437.
19. Gabizon A., Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1992, 1103:94-100.
20. Hong R.L., Tseng Y.L., Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001, 91:1826-1833.
21. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13:238-252.
22. Chingunpitak J., Puttipipatkhachorn S., Chavalitshewinkoon-Petmitr P., Tozuka Y., Moribe K., Yamamoto K. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev. Ind. Pharm. 2008, 34:314-322.
23. Vorauer-Uhl K., Wagner A., Borth N., Katinger H. Determination of liposome size distribution by flow cytometry. Cytometry 2000, 38:166-171.
24. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
25. Garcia-Fuentes M., Torres D., Alonso M.J. Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles. Langmuir 2004, 20:8839-8845.
26. Isacchi B., Bergonzi M.C., Grazioso M., Righeschi C., Pietretti A., Severini C., Bilia A.R. Artemisinin and artemisinin plus curcumin liposomal formulation: enhanced antimalarial efficacy against Plasmodium berghei-infected mice. Eur. J. Pharm. 2012, 80:528-534.
27. Raucher D., Chilkoti A. Enhanced uptake of a thermally responsive polypeptide by tumor cells in response to its hyperthermia-mediated phase transition. Cancer Res. 2001, 61:7163-7170.
28. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991, 1066:29-36.